B M Brenner

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. ncbi request reprint Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
    B M Brenner
    Renal Division, Brigham and Women s Hospital, Boston, MA 02115, USA
    N Engl J Med 345:861-9. 2001
  2. ncbi request reprint AMGEN International Prize: the history and future of renoprotection
    Barry M Brenner
    Harvard Medical School, Renal Division, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Kidney Int 64:1163-8. 2003
  3. ncbi request reprint Renoprotection by enzyme replacement therapy
    Barry M Brenner
    Harvard Medical School, Boston, Massachusetts, USA
    Curr Opin Nephrol Hypertens 13:231-41. 2004
  4. ncbi request reprint Cardiovascular and renal progression factors in chronic kidney disease: a colloquium in honor of John H. Dirks ISN World Congress of Nephrology Singapore, June 26, 2005
    Barry M Brenner
    Harvard Medical School, Boston, Massachusetts 02115, USA
    Kidney Int 68:1411-2. 2005
  5. pmc Remission of renal disease: recounting the challenge, acquiring the goal
    Barry M Brenner
    Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115 6195, USA
    J Clin Invest 110:1753-8. 2002
  6. ncbi request reprint Vasopeptidase inhibition affords greater renoprotection than angiotensin-converting enzyme inhibition alone
    M W Taal
    Renal Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA
    J Am Soc Nephrol 12:2051-9. 2001
  7. ncbi request reprint Proinflammatory gene expression and macrophage recruitment in the rat remnant kidney
    M W Taal
    Renal Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115 6110, USA
    Kidney Int 58:1664-76. 2000
  8. ncbi request reprint Mechanisms underlying renoprotection during renin-angiotensin system blockade
    M W Taal
    Renal Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Am J Physiol Renal Physiol 280:F343-55. 2001
  9. ncbi request reprint Glomeruli and blood pressure. Less of one, more the other?
    B M Brenner
    Renal Division, Brigham and Women s Hospital, Boston, MA 02115
    Am J Hypertens 1:335-47. 1988
  10. ncbi request reprint Current strategies for retarding progression of renal disease
    H S Mackenzie
    Department of Medicine, Brigham and Women s Hospital, and Harvard Medical School, Boston, MA 02115, USA
    Am J Kidney Dis 31:161-70. 1998

Detail Information

Publications58

  1. ncbi request reprint Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
    B M Brenner
    Renal Division, Brigham and Women s Hospital, Boston, MA 02115, USA
    N Engl J Med 345:861-9. 2001
    ..We assessed the role of the angiotensin-II-receptor antagonist losartan in patients with type 2 diabetes and nephropathy...
  2. ncbi request reprint AMGEN International Prize: the history and future of renoprotection
    Barry M Brenner
    Harvard Medical School, Renal Division, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Kidney Int 64:1163-8. 2003
  3. ncbi request reprint Renoprotection by enzyme replacement therapy
    Barry M Brenner
    Harvard Medical School, Boston, Massachusetts, USA
    Curr Opin Nephrol Hypertens 13:231-41. 2004
  4. ncbi request reprint Cardiovascular and renal progression factors in chronic kidney disease: a colloquium in honor of John H. Dirks ISN World Congress of Nephrology Singapore, June 26, 2005
    Barry M Brenner
    Harvard Medical School, Boston, Massachusetts 02115, USA
    Kidney Int 68:1411-2. 2005
  5. pmc Remission of renal disease: recounting the challenge, acquiring the goal
    Barry M Brenner
    Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115 6195, USA
    J Clin Invest 110:1753-8. 2002
  6. ncbi request reprint Vasopeptidase inhibition affords greater renoprotection than angiotensin-converting enzyme inhibition alone
    M W Taal
    Renal Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA
    J Am Soc Nephrol 12:2051-9. 2001
    ..It is concluded that, in this model, OMA affords greater long-term renoprotection than ENA when doses are adjusted to yield equivalent control of SBP...
  7. ncbi request reprint Proinflammatory gene expression and macrophage recruitment in the rat remnant kidney
    M W Taal
    Renal Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115 6110, USA
    Kidney Int 58:1664-76. 2000
    ..Macrophage (Mphi) infiltration may contribute to chronic renal injury. We therefore sought to examine the expression of genes associated with Mphi recruitment in the rat remnant kidney model...
  8. ncbi request reprint Mechanisms underlying renoprotection during renin-angiotensin system blockade
    M W Taal
    Renal Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Am J Physiol Renal Physiol 280:F343-55. 2001
    ..During renin-angiotensin system inhibition, renoprotection is dependent on control of both SBP and UprV. Incomplete suppression of renal cytokine gene expression may also contribute to CRD progression...
  9. ncbi request reprint Glomeruli and blood pressure. Less of one, more the other?
    B M Brenner
    Renal Division, Brigham and Women s Hospital, Boston, MA 02115
    Am J Hypertens 1:335-47. 1988
    ..This may also account for the susceptibility of subsets of Type I and Type II diabetics to develop overt glomerulopathy...
  10. ncbi request reprint Current strategies for retarding progression of renal disease
    H S Mackenzie
    Department of Medicine, Brigham and Women s Hospital, and Harvard Medical School, Boston, MA 02115, USA
    Am J Kidney Dis 31:161-70. 1998
    ..These interventions form the core of current strategies designed to preserve kidney function in patients with chronic renal disease...
  11. ncbi request reprint Non-immunologic predictors of chronic renal allograft failure: data from the United Network of Organ Sharing
    G M Chertow
    Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Kidney Int Suppl 52:S48-51. 1995
    ..These findings may have important biomedical and health care policy implications...
  12. ncbi request reprint Antigen-independent determinants of cadaveric kidney transplant failure
    G M Chertow
    Renal Division, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    JAMA 276:1732-6. 1996
    ..To determine the association of various antigen-independent factors with long-term cadaveric kidney transplant failure...
  13. ncbi request reprint Renal effects of an acute NaCl load in chronic nitric oxide blockade-induced hypertensive rats
    J C Rodriguez-Perez
    Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    J Physiol Biochem 54:127-33. 1998
    ..This observation suggests that in this model of chronic inhibited NO rats, the disposal of an acute sodium load is reached. The existence of a delayed mechanism in renal excretion of Na+ by the chronic NO-blocked rats could be suggested...
  14. ncbi request reprint Renal mass as a determinant of late allograft outcome: insights from experimental studies in rats
    H S Mackenzie
    Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Kidney Int Suppl 52:S38-42. 1995
    ..We conclude that mass-related injury processes may play a potentially major and underappreciated role in the pathogenesis of late renal allograft failure...
  15. ncbi request reprint Glucocorticoids amplify glomerular injury in rats with renal ablation
    D L Garcia
    Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115
    Am J Hypertens 1:54-7. 1988
    ..Thus, potent vasodilator glucocorticoids may amplify hemodynamically mediated glomerular injury, whereas control of systemic and glomerular hypertension prevents this undesirable consequence of chronic steroid therapy...
  16. ncbi request reprint The CHORUS (Cerivastatin in Heart Outcomes in Renal Disease: Understanding Survival) protocol: a double-blind, placebo-controlled trial in patients with esrd
    W F Keane
    Department of Medicine, Hennepin County Medical Center, University of Minnesota Medical School, Minneapolis, MN, USA
    Am J Kidney Dis 37:S48-53. 2001
    ..It will determine whether treatment with cerivastatin can effectively reduce the significant cardiovascular morbidity and mortality...
  17. ncbi request reprint 'Hypertension' and 'microalbuminuria': the bell tolls for thee
    J P Forman
    Harvard Medical School, Boston, Massachusetts, USA
    Kidney Int 69:22-8. 2006
    ..We propose that the medical community consider abandoning the terms 'hypertension' and 'microalbuminuria' in favor of 'blood pressure-associated' and 'albuminuria-associated' disease...
  18. ncbi request reprint Therapeutic benefit of converting-enzyme inhibition in progressive renal disease
    S Anderson
    Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115
    Am J Hypertens 1:380S-383S. 1988
    ..These studies suggest that control of glomerular hypertension may be of special benefit to the patient with progressive renal disease...
  19. ncbi request reprint Pathogenesis of diabetic nephropathy: focus on transforming growth factor-beta and connective tissue growth factor
    O V Sakharova
    Renal Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Curr Opin Nephrol Hypertens 10:727-38. 2001
    ..Thus, acting as a downstream mediator of the profibrotic activity of transforming growth factor-beta, connective tissue growth factor may constitute a more specific target for future antifibrotic therapies...
  20. ncbi request reprint Angiotensin gene polymorphism as a determinant of posttransplantation renal dysfunction and hypertension
    R Abdi
    Renal Division, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Transplantation 72:726-9. 2001
    ....
  21. ncbi request reprint Transcriptional responses to tubule challenges
    S R Gullans
    Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Kidney Int 49:1678-81. 1996
    ..This work highlights the concept that rapid analysis of differential gene expression will enable one to define cellular programs of gene expression involving up- and down-regulation of functionally-related gene families...
  22. ncbi request reprint Adult hypertension and kidney disease: the role of fetal programming
    Kambiz Zandi-Nejad
    Renal Division, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Hypertension 47:502-8. 2006
    ....
  23. ncbi request reprint Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies
    Albert A Carr
    Circulatory Disease Center, Augusta, Georgia, USA
    Am J Cardiol 96:1530-6. 2005
    ..The beneficial effect of losartan on the reduction of risk for hospitalization for new HF was demonstrated in patients who were at high renal and/or high cardiovascular risk...
  24. ncbi request reprint Primary and secondary prevention of chronic kidney disease
    Kambiz Zandi-Nejad
    Renal Division, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Hypertens 23:1771-6. 2005
    ..The most effective of these interventions is based on the inhibition of the renin-angiotensin system (RAS) and is the main focus of this review...
  25. ncbi request reprint Importance of baseline distribution of proteinuria in renal outcomes trials: lessons from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study
    Zhongxin Zhang
    Merck and Co, Inc, P O Box 4, BL 3 4, West Point, PA 19486, USA
    J Am Soc Nephrol 16:1775-80. 2005
    ....
  26. ncbi request reprint Losartan and end-organ protection--lessons from the RENAAL study
    Peter R Kowey
    Main Line Health Heart Center, Wynnewood, Philadelphia, USA
    Clin Cardiol 28:136-42. 2005
    ..Diabetic or renally impaired patients are at high cardiovascular risk, a risk potentially increased in patients with both conditions...
  27. ncbi request reprint Renoprotective effects of renin-angiotensin-system inhibitors
    Dick de Zeeuw
    Lancet 367:899-900; author reply 900-2. 2006
  28. ncbi request reprint Losartan: lessons learned from the RENAAL study
    Shahnaz Shahinfar
    Merck and Co, Inc, Whitehouse Station, New Jersey, USA
    Expert Opin Pharmacother 7:623-30. 2006
    ..The RENAAL study also provided information that will be valuable to those designing future clinical trials in this patient population. This review highlights key findings from the RENAAL study...
  29. ncbi request reprint The impact of losartan on the lifetime incidence of end-stage renal disease and costs in patients with type 2 diabetes and nephropathy
    George W Carides
    Merck and Co Inc, Blue Bell, Pennsylvania 19422, USA
    Pharmacoeconomics 24:549-58. 2006
    ..4 years). The objective of this study was to project the effect of losartan compared with placebo on the lifetime incidence of ESRD and associated costs (from a US healthcare system perspective)...
  30. doi request reprint Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults
    Alberto Ortiz
    Dialysis Unit, Universidad Autonoma de Madrid, Fundacion Jimenez Diaz, Avenida Reyes Catolicos 2, 28040 Madrid, Spain
    Nat Clin Pract Nephrol 4:327-36. 2008
    ..These organ-specific guidelines could be easier to implement than general guidelines, provided they are used in the context of an overall multisystem care approach...
  31. pmc ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy
    Hans Henrik Parving
    Department of Medical Endocrinology, Department 2132, Rigshospitalet, University Hospital of Copenhagen, Blegdamsvej 9, DK 2100 Copenhagen Ø, Denmark
    J Am Soc Nephrol 19:771-9. 2008
    ..In conclusion, proteinuric type 2 diabetic patients with the D allele of the ACE gene have an unfavorable renal prognosis, which can be mitigated and even improved by losartan...
  32. ncbi request reprint Effect of LDL cholesterol and treatment with losartan on end-stage renal disease in the RENAAL study
    Andrew M Tershakovec
    Merck Research Laboratories, Merck and Co, Inc, Upper Gwynedd, Pennsylvania, USA
    Diabetes Care 31:445-7. 2008
    ..LDL cholesterol lowering was associated with a lower risk of ESRD; however, this seemed to be largely an association with the reduction in albuminuria...
  33. ncbi request reprint Fetal programming of adult kidney disease: cellular and molecular mechanisms
    Dov Hershkovitz
    Laboratory of Molecular Medicine, Rambam Health Care Campus, Technion Israel Institute of Technology, Haifa, Israel
    Clin J Am Soc Nephrol 2:334-42. 2007
  34. ncbi request reprint Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study
    William F Keane
    Merck and Co, Inc, Whitehouse Station, New Jersey, USA
    Clin J Am Soc Nephrol 1:761-7. 2006
    ..Future trials with a similar patient population and outcomes measures should consider adjusting analyses for baseline risk factors...
  35. ncbi request reprint Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial
    Wouter B A Eijkelkamp
    Department of Clinical Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
    J Am Soc Nephrol 18:1540-6. 2007
    ..Antihypertensive treatment that is aimed at improving renal outcomes in patients with diabetic nephropathy may therefore require a dual strategy, targeting both SBP and albuminuria reduction...
  36. ncbi request reprint Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension: the RENAAL and LIFE studies
    Wouter B A Eijkelkamp
    Department of Clinical Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
    J Hypertens 25:871-6. 2007
    ....
  37. ncbi request reprint Efficacy and safety of angiotensin II receptor blockade in elderly patients with diabetes
    Wolfgang C Winkelmayer
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, 1620 Tremont St, Suite 3030, Boston, MA 02120, USA
    Diabetes Care 29:2210-7. 2006
    ....
  38. ncbi request reprint Strategies to retard the progression of chronic kidney disease
    Kambiz Zandi-Nejad
    Renal Division, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Med Clin North Am 89:489-509. 2005
    ..The increasing incidence, prevalence, and costs of ESRD are major national health care concerns; interventions that may prevent or slow the progression of CKD towards ESRD are extremely important and the focus of this article...
  39. ncbi request reprint Preventing microalbuminuria in type 2 diabetes
    Kambiz Zandi-Nejad
    N Engl J Med 352:833-4; author reply 833-4. 2005
  40. ncbi request reprint Combination ACEI and ARB therapy: additional benefit in renoprotection?
    Maarten W Taal
    Renal Unit, Derby City General Hospital, Derby DE22 3NE, UK
    Curr Opin Nephrol Hypertens 11:377-81. 2002
    ..In the light of the persisting need for treatments that afford more effective renoprotection, this Special Commentary examines available experimental and clinical evidence in support of this hypothesis...
  41. ncbi request reprint Losartan reduces the costs associated with diabetic end-stage renal disease: the RENAAL study economic evaluation
    William H Herman
    Departments of Internal Medicine and Epidemiology, University of Michigan Health System, Ann Arbor, Michigan 48109 0354, USA
    Diabetes Care 26:683-7. 2003
    ..To evaluate the within-trial effect of losartan and conventional antihypertensive therapy (CT) compared with placebo and CT on the economic cost associated with end-stage renal disease (ESRD)...
  42. ncbi request reprint The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study
    William F Keane
    Department of Medicine, Hennepin County Medical Center, University of Minnesota Medical School, Minneapolis, Minnesota, USA
    Kidney Int 63:1499-507. 2003
    ..We examined the risk factors that predict loss of kidney function (doubling of serum creatinine) or ESRD (dialysis or transplantation) in patients with type 2 diabetes in whom blood pressure was controlled...
  43. ncbi request reprint Analysis of metabolic parameters as predictors of risk in the RENAAL study
    Gerald B Appel
    Division of Nephrology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
    Diabetes Care 26:1402-7. 2003
    ....
  44. ncbi request reprint Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study
    George L Bakris
    Department of Preventive Medicine, Rush Presbyterian St Luke s Medical Center, Rush Medical College, Chicago, IL 60612, USA
    Arch Intern Med 163:1555-65. 2003
    ..Clinical trials of nephropathy in people with type 2 diabetes mellitus have not examined the effects of systolic blood pressure (SBP) or pulse pressure (PP) on the time to end-stage renal disease (ESRD) or death...
  45. ncbi request reprint Impact of the supplementation of kidney mass on blood pressure and progression of kidney disease
    Mai Ots
    Renal Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, USA
    Nephrol Dial Transplant 19:337-41. 2004
    ..To test the hypothesis that nephron mass is an independent determinant of arterial pressure, the effects of augmenting renal mass by isograft transplantation were studied in the model of secondary hypertension...
  46. ncbi request reprint Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes. An Asian perspective from the RENAAL Study
    Juliana C N Chan
    Department of Medicine and Therapeutics, The Chinese University Hong Kong, The Prince of Wales Hospital, Hong Kong, Shatin, China
    Diabetes Care 27:874-9. 2004
    ..In this subgroup analysis, we examined the characteristics, response, and adherence to treatment of the Asian population, as well as their baseline predictors of risk of renal end points...
  47. ncbi request reprint Regarding: "Management of glomerular proteinuria: a commentary"
    Barry M Brenner
    Department of Medicine, Renal Division, Brigham and Women s Hospital, Boston, Massachusetts, USA
    J Am Soc Nephrol 15:1354-5; discussion 1356-7. 2004
  48. ncbi request reprint Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results
    Giuseppe Remuzzi
    Clinical Research Center for Rare Diseases Aldo e Cele Daccò, Mario Negri Institute for Pharmacological Research, Via Gavazzeni 11, 24125 Bergamo, Italy
    J Am Soc Nephrol 15:3117-25. 2004
    ..Angiotensin II antagonism is a suitable and well-tolerated treatment for individuals with type 2 diabetes even with GFR levels approaching renal replacement therapy...
  49. ncbi request reprint Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL
    Dick de Zeeuw
    Department of Clinical Pharmacology, University Medical Center Groningen, Groningen, The Netherlands
    Kidney Int 65:2309-20. 2004
    ....
  50. ncbi request reprint The renoprotective effects of structured care in a clinical trial setting in type 2 diabetic patients with nephropathy
    Wilson Y S Leung
    Department of Medicine and Therapeutics, The Chinese University of Hong Kong, The Prince of Wales Hospital, Shatin, N T, Hong Kong, SAR
    Nephrol Dial Transplant 19:2519-25. 2004
    ..In this subgroup analysis from the RENAAL Study, we hypothesized that the intensive care received by patients in a clinical trial setting also reduced the rate of decline in renal function through optimization of all risk factors...
  51. ncbi request reprint Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy
    Dick de Zeeuw
    Department of Clinical Pharmacology, Groningen University Medical Center, Ant Deusinglaan 1, 9713 AV Groningen, Netherlands
    Circulation 110:921-7. 2004
    ..Albuminuria can be reduced with drugs that block the renin-angiotensin system (RAS). We questioned whether the short-term drug-induced change in albuminuria would predict the long-term cardioprotective efficacy of RAS intervention...
  52. ncbi request reprint Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy
    Anupama Mohanram
    UT Southwestern Medical Center, Dallas, Texas 75390 8856, USA
    Kidney Int 66:1131-8. 2004
    ..Diabetic nephropathy is the leading cause of end-stage renal disease (ESRD). Anemia is common in diabetics with nephropathy; however, the impact of anemia on progression to ESRD has not been carefully examined...
  53. ncbi request reprint Defining renal risk
    Maarten W Taal
    Curr Opin Nephrol Hypertens 16:554-6. 2007
  54. ncbi request reprint From secondary to primary prevention of progressive renal disease: the case for screening for albuminuria
    Paul E de Jong
    University Hospital Groningen, Groningen Institute for Drug Exploration, Groningen, The Netherlands
    Kidney Int 66:2109-18. 2004
    ....
  55. ncbi request reprint Dialysis delayed is death prevented: a clinical perspective on the RENAAL study
    Merlin C Thomas
    The Baker Medical Research Institute, Victoria, Australia
    Kidney Int 63:1577-9. 2003
  56. ncbi request reprint Retarding the progression of renal disease
    Barry M Brenner
    Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Kidney Int 64:370-8. 2003
  57. ncbi request reprint Impact of renin angiotensin system blockade on renal function in health and disease: an end or a beginning?
    Reza Abdi
    Renal Division, Brigham and Women s Hospital, Boston, MA 02115 6392, USA
    Semin Nephrol 24:141-6. 2004
    ..Numerous animal studies as well as recent clinical trials indicate that blockade of the renin angiotensin system effectively retards progression of nephropathy from diverse origins...
  58. ncbi request reprint Chemokine receptor polymorphism and risk of acute rejection in human renal transplantation
    Reza Abdi
    Renal Division, Brigham and Women s Hospital, Boston, Massachesetts, USA
    J Am Soc Nephrol 13:754-8. 2002
    ..20; P = 0.032) and homozygosity for the 59029-A allele (OR, 0.26; P = 0.027). It was concluded that the risk of acute rejection in renal transplantation is associated with genetic variation in the chemokine receptors CCR2 and CCR5...